This ESMO Guideline provides key recommendations on the role of PROMs during the care of patients with cancer. It covers the use of PROMs in patients with cancer from the start of active treatment during follow-up to the end of life. Recommendations are based on available scientific evidence and the authors’ collective expert consensus. Authorship includes a multidisciplinary group of experts from Europe, North America, Asia and Australia.
The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline
Di Maio, MFirst
;
2022-01-01
Abstract
This ESMO Guideline provides key recommendations on the role of PROMs during the care of patients with cancer. It covers the use of PROMs in patients with cancer from the start of active treatment during follow-up to the end of life. Recommendations are based on available scientific evidence and the authors’ collective expert consensus. Authorship includes a multidisciplinary group of experts from Europe, North America, Asia and Australia.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
PIIS0923753422006913.pdf
Open Access dal 22/04/2023
Descrizione: Journal pre-proof (open access)
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
5.93 MB
Formato
Adobe PDF
|
5.93 MB | Adobe PDF | Visualizza/Apri |
|
The role of patient-reported outcome measures in the continuum of cancer clinical care ESMO Clinical Practice Guideline.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
569.73 kB
Formato
Adobe PDF
|
569.73 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
